Correction to: The Therapy of Congenital Myasthenic Syndromes (Neurotherapeutics, (2007), 4, 2, (252-257), 10.1016/j.nurt.2007.01.001);The Therapy of Congenital Myasthenic Syndromes

Neurotherapeutics

Volumn 4, Issue 2, 2007, Pages 252-257

  Engel, Andrew G ^a  

^a MAYO CLINIC   (United States)

Author keywords

3,4 diaminopyridine; acetylcholine receptor; acetylcholinesterase; choline acetyltransferase; cholinesterase inhibitors; Congenital myasthenic syndromes; Dok 7; fluoxetine; MuSK; quinidine; rapsyn

Indexed keywords

3,4 DIAMINOPYRIDINE; ACETYLCHOLINE; ANTIARRHYTHMIC AGENT; CHOLINE ACETYLTRANSFERASE; CHOLINERGIC RECEPTOR; CHOLINESTERASE INHIBITOR; CIMETIDINE; CODEINE; DIGOXIN; EPHEDRINE; EPHEDRINE SULFATE; FLUOXETINE; NEOSTIGMINE METHYL SULFATE; PREDNISONE; PROTEIN DOK7; PYRIDOSTIGMINE; QUINIDINE SULFATE; RAPSYN; REGULATOR PROTEIN; TRICYCLIC ANTIDEPRESSANT AGENT; UNCLASSIFIED DRUG; VERAPAMIL; WARFARIN;

AGRANULOCYTOSIS; ARTICLE; ATRIOVENTRICULAR JUNCTION ARRHYTHMIA; BRONCHUS SECRETION; CHANNEL GATING; CINCHONISM; CONGENITAL MYASTHENIC SYNDROME; COUGHING; DIARRHEA; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DRUG DOSE INCREASE; DRUG EFFECT; DRUG EFFICACY; DRUG ERUPTION; DRUG RESPONSE; DRUG SAFETY; DRUG USE; ENZYME DEFICIENCY; FEVER; GASTROINTESTINAL SYMPTOM; HEART PALPITATION; HEART VENTRICLE EXTRASYSTOLE; HEMOLYTIC ANEMIA; HUMAN; HYPERTENSION; HYPONATREMIA; INCIDENCE; INSOMNIA; LIVER FUNCTION TEST; NAUSEA; NERVOUSNESS; NEUROMUSCULAR SYNAPSE; PARESTHESIA; PERIORAL PARESTHESIA; PERIPHERAL PARESTHESIA; PREVALENCE; PRIORITY JOURNAL; QT PROLONGATION; RECOMMENDED DRUG DOSE; SEXUAL DYSFUNCTION; SIDE EFFECT; SUICIDE; SYNAPTIC TRANSMISSION; THROMBOCYTOPENIC PURPURA;

EID: 33947497536     PISSN: 19337213     EISSN: 18787479     Source Type: Journal    
DOI: 10.1007/s13311-018-00672-6     Document Type: Erratum

References (46)

1. Salpeter M.M. Vertebrate neuromuscular junctions: general morphology, molecular organization, and functional consequences. In: Salpeter M.M. (Ed). The vertebrate neuromuscular junction (1987), Wiley, New York 1-54
2. Flucher B.E., and Daniels M.P. Distribution of Na+ channels and ankyrin in neuromuscular junctions is complementary to that of acetylcholine receptors and the 43 kd protein. Neuron 3 (1989) 163-175
3. Ruff R.L. Sodium channel slow inactivation and the distribution of sodium channels on skeletal muscle fibres enable the performance properties of different skeletal muscle fiber types. Acta Physiol Scand 156 (1996) 159-168
4. Martin A.R. Amplification of neuromuscular transmission by postjunctional folds. Proc R Soc Lond B Biol Sci 258 (1994) 321-326
5. Wood S.J., and Slater C.P. Safety factor at the neuromuscular junction. Prog Neurobiol 64 (2001) 393-429
6. Engel A.G., Ohno K., Milone M., et al. New mutations in acetylcholine receptor subunit genes reveal heterogeneity in the slow-channel congenital myasthenic syndrome. Hum Mol Genet 5 (1996) 1217-1227
7. Ohno K., Tsujino A., Brengman J.M., et al. Choline acetyltransferase mutations cause myasthenic syndrome associated with episodic apnea in humans. Proc Natl Acad Sci U S A 98 (2001) 2017-2022
8. Engel A.G. The investigation of congenital myasthenic syndromes. Ann NY Acad Sci 681 (1993) 425-434
9. Fukudome T., Ohno K., Brengman J.M., and Engel A.G. Quinidine normalizes the open duration of slow-channel mutants of the acetylcholine receptor. Neuroreport 9 (1998) 1907-1911
10. Harper C.M., Fukudome T., and Engel A.G. Treatment of slow channel congenital myasthenic syndrome with fluoxetine. Neurology 60 (2003) 170-173
11. Ohno K., Brengman J.M., Tsujino A., and Engel A.G. Human endplate acetylcholinesterase deficiency caused by mutations in the collagen-like tail subunit (ColQ) of the asymmetric enzyme. Proc Natl Acad Sci U S A 95 (1998) 9654-9659
12. Ohno K., Quiram P.A., Milone M., et al. Congenital myasthenic syndromes due to heteroallelic nonsense/missense mutations in the acetylcholine receptor e subunit gene: identification and functional characterization of six new mutations. Hum Mol Genet 6 (1997) 753-766
13. Ohno K., Engel A.G., Shen X.M., et al. Rapsyn mutations in humans cause endplate acetylcholine receptor deficiency and myasthenic syndrome. Am J Hum Genet 70 (2002) 875-885
14. Chevessier F., Faraut B., Ravel-Chapuis A., et al. MUSK, a new target for mutations causing congenital myasthenic syndrome. Hum Mol Genet 13 (2004) 3229-3240
15. Beeson D., Higuchi O., Palace J., et al. Dok-7 mutations underlie a neuromuscular junction synaptopathy. Science 313 (2006) 1975-1978
16. Ohno K., Anlar B., Ozdirim E., Brengman J.M., DeBleecker J.L., and Engel A.G. Myasthenic syndromes in Turkish kinships due to mutations in the acetylcholine receptor. Ann Neurol 44 (1998) 234-241
17. Middleton L., Ohno K., Christodoulou K., and Sine S.M. Congenital myasthenic syndromes linked to chromosome 17p are caused by defects in acetylcholine receptor e subunit gene. Neurology 53 (1999) 1076-1082
18. Croxen R., Hatton C., Shelley C., et al. Recessive inheritance and variable penetrance of slow-channel congenital myasthenic syndromes. Neurology 59 (2002) 162-168
19. Maeno T. Kinetic analysis of a large facilitatory action of 4-aminopyridine on the motor nerve terminal of the neuromuscular junction. Proc Jpn Acad 56 (1980) 241-245
20. Saint D.A. The effects of 4-aminopyridine and tetraethylammonium on the kinetics of transmitter release at the mammalian neuromuscular synapse. Can J Physiol Pharmacol 67 (1989) 1045-1050
21. McEvoy K.M., Windebank A.J., Daube J.R., and Low P.A. 3,4-Diaminopyridine in the treatment of Lambert-Eaton myasthenic syndrome. N Engl J Med 321 (1989) 1567-1571
22. Sanders D.B., Howard Jr. J.F., and Massey J.M. 3,4-diaminopyridine in Lambert-Eaton myasthenic syndrome and myasthenia gravis. Ann NY Acad Sci 681 (1993) 588-590
23. Harper C.M., and Engel A.G. Treatment of 31 congenital myasthenic syndrome patients with 3,4-diaminopyridine. Neurology 54 suppl 3 (2000) A395
24. Palace J., Wiles C.M., and Newsom-Davis J. 3,4-diaminopyridine in the treatment of congenital (hereditary) myasthenia. J Neurol Neurosurg Psychiatry 54 (1991) 1069-1072
25. Anlar B., Varli K., Ozdirim E., and Ertan M. 3,4-diaminopyridine in childhood myasthenia: double blind, placebo controlled trial. J Child Neurol 11 (1996) 458-461
26. Engel A.G., Ohno K., Bouzat C., Sine S.M., and Griggs R.G. End-plate acetylcholine receptor deficiency due to nonsense mutations in the e subunit. Ann Neurol 40 (1996) 810-817
27. Engel A.G., Ohno K., and Sine S.M. Sleuthing molecular targets for neurological diseases at the neuromuscular junction. Nat Rev Neurosci 4 (2003) 339-352
28. Harper C.M., and Engel A.G. Quinidine sulfate therapy for the slow-channel congenital myasthenic syndrome. Ann Neurol 43 (1998) 480-484
29. Drug Evaluations Annual. 7th ed. (1995), American Medical Association, Milwaukee, WI 677-679
30. Drug Evaluations Annual. 7th ed. (1995), American Medical Association, Milwaukee, WI 310-311
31. Whittington C.J., Kendall T., and Pilling S. Are the SSRIs and atypical antidepressants safe and effective for children and adolescents?. Curr Opin Psychiatry 18 (2005) 21-25
32. Bailly D. Efficacy of selective serotonin reuptake inhibitor treatment in children and adolescents. Presse Med 35 (2006) 1293-1302
33. Engel A.G., Ohno K., and Sine S.M. Congenital myasthenic syndromes. In: Engel A.G. (Ed). Myasthenia gravis and myasthenic disorders (1999), Oxford University Press, New York 251-297
34. Bestue-Cardiel M., Saenz de Cabezon-Alvarez A., Capablo-Liesa J.L., et al. Congenital endplate acetylcholinesterase deficiency responsive to ephedrine. Neurology 65 (2005) 144-146
35. Hutchinson D.O., Walls T.J., Nakano S., et al. Congenital endplate acetylcholinesterase deficiency. Brain 116 (1993) 633-653
36. Breningstall G.N., Kurachek S.C., Fugate J.H., and Engel A.G. Treatment of congenital endplate acetylcholinesterase deficiency by neuromuscular blockade. J Child Neurol 11 (1996) 345-346
37. Burke G., Cossins J., Maxwell S., et al. Rapsyn mutations in hereditary myasthenia: distinct early- and late-onset phenotypes. Neurology 61 (2003) 826-828
38. Banwell B.L., Ohno K., Sieb J.P., and Engel A.G. Novel truncating RAPSN mutation causing congenital myasthenic syndrome responsive to 3,4-diaminopyridine. Neuromuscul Disord 14 (2004) 202-207
39. Okada K., Inoue A., Okada M., et al. The muscle protein Dok-7 is essential for neuromuscular synaptogenesis. Science 312 (2006) 1802-1805
40. Slater C.R., Fawcett P.R.W., Walls T.J., et al. Pre- and postsynaptic abnormalities associated with impaired neuromuscular transmission in a group of patients with 'limb-girdle myasthenia'. Brain 129 (2006) 2061-2076
41. Walls T.J., Engel A.G., Nagel A.S., Harper C.M., and Trastek V.F. Congenital myasthenic syndrome associated with paucity of synaptic vesicles and reduced quantal release. Ann N Y Acad Sci 681 (1993) 461-468
42. Tim R.W., Massey J.M., and Sanders D.B. Lambert-Eaton myasthenic syndrome: electrodiagnostic findings and response to treatment. Neurology 54 (2000) 2176-2178
43. Banwell B.L., Russel J., Fukudome T., Shen X.M., Stilling G., and Engel A.G. Myopathy, myasthenic syndrome, and epidermolysis bullosa simplex due to plectin deficiency. J Neuropathol Exp Neurol 58 (1999) 832-846
44. Tsujino A., Maertens C., Ohno K., et al. Myasthenic syndrome caused by mutation of the SCN4A sodium channel. Proc Natl Acad Sci U S A 100 (2003) 7377-7382
45. Engel A.G., Lambert E.H., Mulder D.M., et al. A newly recognized congenital myasthenic syndrome attributed to a prolonged open time of the acetylcholine-induced ion channel. Ann Neurol 11 (1982) 553-569
46. Byring R.F., Pihko H., Tsujino A., et al. Congenital myasthenic syndrome associated with episodic apnea and sudden infant death. Neuromuscul Disord 12 (2002) 548-553